Concise Review: The Regenerative Journey of Pericytes Toward Clinical Translation.
Concise Review: The Regenerative Journey of Pericytes Toward Clinical Translation.
复制标题
DOI：
10.1002/stem.2846
复制
发表时间：
2018-09
期刊：
影响因子：
--
通讯作者：
Madeddu P
中科院分区：
文献类型：
--
作者：
Cathery W;Faulkner A;Maselli D;Madeddu P
冠状动脉疾病(CAD)是世界范围内最主要的死亡原因。治疗和管理方面的进步显著改善了患者的预后。另一方面，尽管死亡率有所下降，但更多的人留下了需要额外治疗和住院的后遗症。此外，严重不能再血运重建的冠心病患者仍然只有心脏移植的选择，这受到合适供者短缺的限制。近年来，基于细胞的再生疗法已经成为一种可能的替代治疗方法，几种再生医学产品已经进入临床开发阶段，其他一些已经成为具有竞争力的临床前解决方案。最近的证据表明，周细胞，即血管微血管的壁细胞，是一种很有前途的治疗候选细胞。周细胞在人体内含量丰富，在血管生成、血管稳定和血流调节中发挥着积极的作用，并具有向间充质系多细胞分化的能力。此外，早期研究表明，它们对低氧侮辱具有健壮性，使它们具有抵御缺血微环境的独特装备。本文综述了以周细胞为基础的细胞治疗的基本原理及其在临床应用方面的进展。我们介绍了周细胞的不同来源，以及从心血管手术后残留的组织中获取周细胞的情况。我们还讨论了周细胞在临床前心肌缺血(MI)动物模型中的愈合潜力，以及目前升级生产方案以转移到临床的做法。这些程序的标准化是最重要的，因为细胞制造中缺乏一致性可能会影响临床结果。干细胞2018；36：1295-1310
Coronary artery disease (CAD) is the single leading cause of death worldwide. Advances in treatment and management have significantly improved patient outcomes. On the other hand, although mortality rates have decreased, more people are left with sequelae that require additional treatment and hospitalization. Moreover, patients with severe nonrevascularizable CAD remain with only the option of heart transplantation, which is limited by the shortage of suitable donors. In recent years, cell‐based regenerative therapy has emerged as a possible alternative treatment, with several regenerative medicinal products already in the clinical phase of development and others emerging as competitive preclinical solutions. Recent evidence indicates that pericytes, the mural cells of blood microvessels, represent a promising therapeutic candidate. Pericytes are abundant in the human body, play an active role in angiogenesis, vessel stabilization and blood flow regulation, and possess the capacity to differentiate into multiple cells of the mesenchymal lineage. Moreover, early studies suggest a robustness to hypoxic insult, making them uniquely equipped to withstand the ischemic microenvironment. This review summarizes the rationale behind pericyte‐based cell therapy and the progress that has been made toward its clinical application. We present the different sources of pericytes and the case for harvesting them from tissue leftovers of cardiovascular surgery. We also discuss the healing potential of pericytes in preclinical animal models of myocardial ischemia (MI) and current practices to upgrade the production protocol for translation to the clinic. Standardization of these procedures is of utmost importance, as lack of uniformity in cell manufacturing may influence clinical outcome. Stem Cells 2018;36:1295–1310
登录
查看更多内容
骨髓来源的多能细胞是有助于血管化的周细胞
影响因子：
4.8
作者：
Cai, Xiaoxiao;Lin, Yunfeng;Grottkau, Brian E.
通讯作者：
Grottkau, Brian E.
影响因子：
5.6
作者：
Al Ahmad, A.;Gassmann, M.;Ogunshola, O. O.
通讯作者：
Ogunshola, O. O.
DOI：
10.1023/a:1011965307612
发表时间：
2001-01-01
期刊：
JOURNAL OF NEUROCYTOLOGY
影响因子：
--
作者：
Bandopadhyay, R;Orte, C;Allt, G
通讯作者：
Allt, G
分子机制和血管生成的临床应用。
影响因子：
64.8
作者：
Carmeliet, Peter;Jain, Rakesh K.
通讯作者：
Jain, Rakesh K.
影响因子：
20.1
作者：
Bolli R
通讯作者：
Bolli R